Releaf Becomes First B Corp Certified Medical Cannabis Company

What B Corp Certification Means for Cannabis Operators

B Corp certification requires a minimum verified score of 80 on the B Impact Assessment, a 200-question audit covering governance, worker treatment, community engagement, environmental footprint, and customer impact. The nonprofit B Lab administers the credential, which is held by brands including Patagonia, Ben & Jerry's, and Allbirds. Releaf scored 91.3 on the assessment, according to the company's July 13 announcement.

Cannabis companies face structural barriers to ESG certification. Federal Schedule I status in the U.S. disqualifies most operators from mainstream capital markets and institutional ESG funds. Banking restrictions limit transparency tools. Releaf operates exclusively in the UK medical market under Home Office licensing, sidestepping many of those constraints.

The certification audit reviewed Releaf's supply-chain labor practices, its patient-access programs, waste-management protocols at cultivation facilities, and board governance structures. B Lab doesn't disclose scoring breakdowns publicly, but the 91.3 total places Releaf in the top quartile of certified companies across all industries.

Releaf's Operational Model and Market Position

Releaf operates a vertically integrated medical cannabis platform in the UK, combining telemedicine consultations, in-house pharmacy dispensing, and contract cultivation partnerships. The company reported 45,000 active patients as of June 2026, a 220 percent year-over-year increase. It doesn't sell recreational products and doesn't hold licenses in any U.S. state.

Revenue depends on subscription telemedicine fees and per-gram product margins. Average patient spend runs £150 per month, according to Releaf's Q2 investor update. The firm raised £12 million in Series B funding in March 2026 from European venture funds, including Backed VC and Octopus Ventures.

UK medical cannabis sales reached £102 million in 2025, up from £31 million in 2023, driven by expanded prescribing categories and the 2024 NICE guidance update that recognized cannabis-based medicinal products for chronic pain and epilepsy. By patient count, Releaf holds an estimated 18 percent market share, trailing only Sapphire Medical Clinics.

Why B Corp Status Matters for Cannabis Capital Access

The certification opens institutional capital channels that remain closed to most cannabis operators, particularly in Europe where ESG mandates govern pension-fund and sovereign-wealth allocations. EU taxonomy regulations and the UK's Sustainable Disclosure Requirements both reference third-party ESG certifications as eligibility screens. Releaf's CFO, David Haddad, said in the announcement that the certification "de-risks us for institutional LPs who need a checkbox."

B Corp status doesn't guarantee access to U.S. institutional capital. Federal illegality still bars most pension funds, endowments, and ESG-labeled ETFs from holding cannabis equity, even for non-U.S. operators. But European asset managers, including Nordea and Amundi, have launched ESG funds that explicitly include certified B Corps in vice-exclusion categories, creating a narrow entry point.

The certification also carries reputational weight in medical markets where patient trust and prescriber confidence hinge on perceived legitimacy. For background on how ESG frameworks intersect with cannabis policy, see the CannIntel topic hub on Cannabis B Corp Certification.

What Other Cannabis Companies Are Watching

No U.S. multi-state operator has pursued B Corp certification, largely because the audit process requires full financial transparency and federal banking integration that 280E tax treatment and SAFE Banking Act failures make impractical. Canadian licensed producers, including Tilray and Aurora, have explored the credential but haven't completed the assessment. The audit timeline runs 12 to 18 months. Costs range from $25,000 to $150,000 depending on company size.

Releaf's certification may accelerate interest among European and Australian medical operators. Germany's April 2024 legalization created a medical-only market structure similar to the UK's, and operators there face identical capital-access challenges. Australia's Cannatrek and Little Green Pharma have both signaled interest in third-party ESG credentials, according to investor presentations reviewed by CannIntel.

The next milestone: whether any U.S. ancillary firm—software, testing labs, packaging—pursues the credential. Those businesses face none of the federal barriers that block plant-touching operators, but none have moved yet. The math is brutal for MSOs. Until SAFE Banking or rescheduling lands, the audit trail B Lab requires simply doesn't exist in a cash-heavy, 280E-constrained operating environment.

We'll be watching whether German and Australian operators file B Lab applications in Q3 2026, and whether any U.S. ancillary moves first.